Contrasting of Kezar Life Sciences Inc. (KZR) and Blueprint Medicines Corporation (NASDAQ:BPMC)

Both Kezar Life Sciences Inc. (NASDAQ:KZR) and Blueprint Medicines Corporation (NASDAQ:BPMC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kezar Life Sciences Inc. N/A 0.00 19.68M -1.05 0.00
Blueprint Medicines Corporation 45.12M 70.66 205.35M -4.79 0.00

Table 1 highlights Kezar Life Sciences Inc. and Blueprint Medicines Corporation’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Kezar Life Sciences Inc. 0.00% 0% 0%
Blueprint Medicines Corporation -455.12% -36.7% -31%


The current Quick Ratio of Kezar Life Sciences Inc. is 32.9 while its Current Ratio is 32.9. Meanwhile, Blueprint Medicines Corporation has a Current Ratio of 10.1 while its Quick Ratio is 10.1. Kezar Life Sciences Inc. is better positioned to pay off its short-term and long-term debts than Blueprint Medicines Corporation.

Analyst Recommendations

The Ratings and Recommendations for Kezar Life Sciences Inc. and Blueprint Medicines Corporation are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kezar Life Sciences Inc. 0 0 0 0.00
Blueprint Medicines Corporation 0 0 1 3.00

Meanwhile, Blueprint Medicines Corporation’s consensus target price is $105, while its potential upside is 44.77%.

Insider and Institutional Ownership

The shares of both Kezar Life Sciences Inc. and Blueprint Medicines Corporation are owned by institutional investors at 47.5% and 0% respectively. About 22.8% of Kezar Life Sciences Inc.’s share are held by insiders. Insiders Competitively, held 0.1% of Blueprint Medicines Corporation shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kezar Life Sciences Inc. -9.94% 16.22% 45.19% 0% 0% 50.59%
Blueprint Medicines Corporation 3.22% -13.13% -21.78% -15.8% -17.24% -21.47%

For the past year Kezar Life Sciences Inc. had bullish trend while Blueprint Medicines Corporation had bearish trend.


On 7 of the 10 factors Kezar Life Sciences Inc. beats Blueprint Medicines Corporation.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. In addition, the company is developing treatments that target cancer and rare genetic diseases. The company has agreements with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.